Contains Proteins Or Derivative Or Polysaccharides Or Derivative Patents (Class 424/499)
  • Patent number: 11491090
    Abstract: The present invention relates to compositions of spherical microparticles composed of a wall material and at least one cavity that comprises a gas and/or a liquid, which have pores on the surface thereof, wherein the spherical microparticles have a mean particle diameter of 10-600 ?m and wherein at least 80% of those microparticles, the particle diameter of which does not deviate from the mean particle diameter of the microparticles of the composition by more than 20%, each have on average at least 10 pores, the diameter of which is in the range from 1/5000 to ? of the mean particle diameter, and, furthermore, the diameter of each of these pores is at least 20 nm, wherein the wall material consists of a composition comprising at least one aliphatic-aromatic polyester, and the wall material has a solubility at 25° C. of at least 50 g/l in dichloromethane, a method for the preparation thereof and also the use thereof.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: November 8, 2022
    Inventors: Ewelina Burakowska-Meise, Wolfgang Krause, Patrick Leibach, Karl Kolter
  • Patent number: 11466057
    Abstract: It has been found that an extracellular polypeptide derived from Akkermansia municiphila is capable of modulating and/or promoting gut mucosal immune system function and/or maintaining and/or restoring metabolic status and/or increasing the physical integrity of the gut mucosal barrier in a mammal. The polypeptide or host cells comprising such polypeptide may be employed to prevent and/or treat a variety of conditions that benefit from an increased physical integrity of the gut mucosal barrier and/or an improved gut mucosal immune system function and metabolic status.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: October 11, 2022
    Assignees: WAGENINGEN UNIVERSITEIT, UNIVERSITÉ CATHOLIQUE DE LOUVAIN
    Inventors: Clara Belzer, Willem Meindert De Vos, Patrice Daniel Cani
  • Patent number: 11427637
    Abstract: Described herein are methods, formulations and kits for treating a patient with cancer with nanoparticle complexes comprising a carrier protein, a binding agent and paclitaxel and optionally co-treated with an anti-PD-L1 antibody.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: August 30, 2022
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 11331270
    Abstract: The present application relates to a pharmaceutical composition in a form of dry powder for intranasal administration, comprising solid particles of at least one active agent and solid particles of a diluent, said pharmaceutical composition being substantially free of excipients other than the solid diluent, wherein said pharmaceutical composition having at least 90% of the particles of said at least one active agent with a mean particle size of 10-30 microns and less than 10% of the particles of said at least one active agent with a mean particle size equal to or below 5 microns. The particles of said diluent have a mean particle size of 30-200 microns. The present application also relates to an apparatus and modified spray drying method for preparation of the pharmaceutical composition of the present invention in the dry powder form.
    Type: Grant
    Filed: August 19, 2018
    Date of Patent: May 17, 2022
    Assignee: Nasus Pharma Ltd.
    Inventor: Galia Temtsin-Krayz
  • Patent number: 11319367
    Abstract: Disclosed herein are methods of reducing a symptom of respiratory disease in a pre-weaned milk-fed mammal by orally administering an isolated antibody that specifically binds the interleukin-10 peptide or an anti-interleukin-10 antibody. Also included are methods of reducing mixing stress in human and non-human mammals by administering an isolated antibody that specifically binds the interleukin-10 peptide or an anti-interleukin-10 antibody. Further included are milk and food compositions including the interleukin-10 peptide or anti-interleukin-10 antibody.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: May 3, 2022
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Mark Eric Cook, Jordan Marshall Sand, Sheila Mary McGuirk, Jane Ellen Rieman, Sarah Marie Raabis
  • Patent number: 11260025
    Abstract: An in situ gelling composition comprising nanoparticles comprising soy protein and a bioactive agent, and a sodium alginate film, wherein the nanoparticles are encapsulated in the film. The in situ gelling composition maybe incorporated into a solid dosage form or reconstituted with water for oral administration to a subject in need of sustained release of the bioactive agent.
    Type: Grant
    Filed: February 15, 2021
    Date of Patent: March 1, 2022
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Shadab MD, Samaa T. Abdullah, Nabil A. Alhakamy
  • Patent number: 11260359
    Abstract: The microcapsules and process of making describe a novel core shell microcapsule. The microcapsule incorporates a polysaccharide such as chitosan into the microcapsule wall forming the shell. The microcapsule shell is formed by dissolving chitosan into a material of structure wherein each R is independently selected from hydrogen, C1 to C8 alkyl, or a cyano group; and each y is independently an integer from 1 to 8, and reacting with a multifunctional (meth)acrylate.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: March 1, 2022
    Inventors: Presley Genevie Neuman, Linsheng Feng
  • Patent number: 11202766
    Abstract: Novel hydrocodone bitartrate and guaifenesin pharmaceutical compositions. Methods of making and using the hydrocodone bitartrate and guaifenesin pharmaceutical compositions also are disclosed.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: December 21, 2021
    Assignee: ECI Pharmaceuticals, LLC
    Inventors: Solomon Goll, Nirali R. Bhatt
  • Patent number: 11202757
    Abstract: A pharmaceutical composition in a form of dry powder for intranasal administration includes solid particles of at least one opioid receptor antagonist as active ingredient and two types of solid particles. A naloxone pharmaceutical composition in the form of dry powder for intranasal administration, including as active agent naloxone or a pharmaceutically acceptable salt thereof. A kit for intranasal administration of naloxone. A method of treating opioid overdose/intoxication and/or a symptom thereof in a patient in need thereof by intranasally administering a therapeutically effective amount of a composition including solid particles of at least one opioid receptor antagonist as active ingredient and two types of solid particles.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: December 21, 2021
    Assignee: Formulex Pharma Innovations Ltd.
    Inventors: Galia Temtsin-Krayz, Dalia Megiddo, Tair Lapidot, Carolina Abrutzky
  • Patent number: 11185122
    Abstract: Sports boot element comprising all or part of a wall designed to form at least part of a lateral and/or frontal and/or rear and/or lower wall of a sports boot, characterised in that all or part of its wall comprises a material (10) comprising a polymer (11) and a hollow microball (12) filler.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: November 30, 2021
    Assignee: ROSSIGNOL LANGE S.R.L.
    Inventor: Matteo Stefan
  • Patent number: 11185093
    Abstract: The present invention relates to pulverulent compositions of at least one carotenoid selected from the group consisting of ?-carotene, astaxanthin, canthaxanthin, citranaxanthin, lycopene and lutein, a process for the production of these pulverulent compositions, and the use of the pulverulent compositions.
    Type: Grant
    Filed: November 11, 2008
    Date of Patent: November 30, 2021
    Inventor: Christian Köpsel
  • Patent number: 11179414
    Abstract: Disclosed is a method for producing a protease degradation composition by degrading a composition containing a hyaluronic acid and a protein with a protease, in the presence of an ascorbic acid, an ascorbate or a salt thereof. The composition produced according to the method has a high fibroblast proliferation promoting effect and a high collagen production promoting effect.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: November 23, 2021
    Assignee: LAIMU CORPORATION
    Inventor: Sachio Wakayama
  • Patent number: 11154570
    Abstract: The present invention generally relates to iron-polysaccharide (polydextrose) complexes and methods for the preparation thereof. In particular, the present invention relates to iron-polydextrose complexes and methods for the preparation thereof. The inventive complexes are suitable for use in various compositions, including particulate compositions that may be incorporated in various forms of administration, including tablets, capsules, and intravenous formulations. The complexes and compositions of the present invention are suitable for use in the treatment of iron deficient anemia. Advantageously, in addition to providing iron supplementation the complexes and compositions of the present invention provide certain advantages based on the presence of polydextrose (e.g., its low glycemic index and high fiber content).
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: October 26, 2021
    Assignee: Particle Dynamics International, LLC.
    Inventors: Paul Brady, Keith Cromack
  • Patent number: 11116723
    Abstract: A pharmaceutical composition in a form of dry powder for intranasal administration includes solid particles of at least one active agent and solid particles of a diluent. The pharmaceutical composition is substantially free of excipients other than the solid diluent. The pharmaceutical composition has at least 90% of the particles of the at least one active agent with a mean particle size of 10-30 microns and less than 10% of the particles of the at least one active agent with a mean particle size equal to or below 5 microns. The particles of the diluent have a mean particle size of 30-200 microns. An apparatus and method for preparation of the pharmaceutical composition utilize a spray-drying chamber, a cyclone separator, and a receiving chamber.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: September 14, 2021
    Assignee: Formulex Pharma Innovations Ltd.
    Inventor: Galia Temtsin-Krayz
  • Patent number: 11110151
    Abstract: An ultra-rapid acting insulin composition and method for treating hyperglycemia in patients with diabetes are disclose. The composition is an inhalable dry powder composition comprising fumaryl diketopiperazine and insulin for pulmonary delivery, which significantly reduces the rates of hypoglycemic events in patients in patients on mealtime insulin therapy.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: September 7, 2021
    Assignee: MannKind Corporation
    Inventors: Marshall Grant, Simon R. Bruce, Robert A. Baughman
  • Patent number: 11103501
    Abstract: A spray dried-powder composition for inhalation comprising particles (X) containing (a) between 5 and 50% by weight of at least one azole derivative in amorphous state but not in crystalline structure and (b) at least one matricial agent to the composition selected from a group consisting of polyol such as sorbitol, mannitol and xylitol; a monosaccharides such as glucose and arabinose; disaccharide such as lactose, maltose, saccharose and dextrose; cholesterol, and any mixture thereof, wherein the composition provides a dissolution rate of said azole derivative of at least, 5% within 10 minutes, 10% within 20 minutes and 40% within 60 minutes when tested in the dissolution apparatus type 2 of the United States Pharmacopoeia at 50 rotation per minute, 37° C. in 900 milliliters of an aqueous dissolution medium adjusted at pH 1.2 and containing 0.3% of sodium laurylsulfate.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: August 31, 2021
    Inventors: Arthur Deboeck, Francis Vanderbist, Philippe Baudier, Thami Sebti, Christophe Duret, Karim Amighi
  • Patent number: 11065238
    Abstract: The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: July 20, 2021
    Assignees: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, APHP (ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS), ÉCOLE PRATIQUE DES HAUTES ÉTUDES
    Inventors: Frédéric Darios, Giovanni Stevanin, Fanny Mochel, Julien Branchu, Maxime Boutry
  • Patent number: 11045492
    Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: June 29, 2021
    Assignee: onCour Pharma, Inc.
    Inventor: John Puisis
  • Patent number: 11045464
    Abstract: This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: June 29, 2021
    Assignee: VeroScience LLC
    Inventor: Anthony H. Cincotta
  • Patent number: 11033602
    Abstract: Disclosed herein is a pulmonary administration device, comprising a spray nozzle unit and a cartridge containing an aqueous solution comprising from 70 to 400 mg A/m L of a sulfomethylated polymyxin, and use of sulfomethylated polymyxin in a device for pulmonary administration in a patient in need thereof.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: June 15, 2021
    Assignee: XELLIA PHARMACEUTICALS APS
    Inventor: Nenad Bencic
  • Patent number: 11013736
    Abstract: The invention discloses an oral solid preparation containing any one, or a mixture of two or more of crystalline form I, II, III, and IV of the compound represented by formula (A). The oral solid preparation of the present invention disintegrates rapidly, increasing dissolution rate thereof, thereby improving bioavailability. In particular, it is possible to solve the problem that an active material (active ingredient), which is high hygroscopic and becomes sticky after moisture absorption, can not be effectively disintegrated by conventional disintegrants. The present invention further relates to a use of the oral solid preparation in preparing an angiotensin II receptor antagonist or a use thereof in preparing medicine for preventing and/or treating hypertension, chronic heart failure and diabetic nephropathy.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: May 25, 2021
    Assignee: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD.
    Inventors: Lei Liang, Yongkai Chen, Liu Hu, Wei Feng, Chaodong Wang
  • Patent number: 11007279
    Abstract: A major challenge in non-viral gene delivery remains finding a safe and effective delivery system. Colloidally stable non-viral gene vector delivery systems capable of overcoming various biological barriers, are disclosed. The gene vectors are biodegradable, non-toxic and highly tailorable for use in specific applications. The vectors include a mixture of biodegradable copolymers, such as PBAE, and biodegradable polymers conjugated with hydrophilic, neutrally charged polymer, such as PEG. The gene vectors demonstrate broad vector distribution and high transgene delivery in vivo, providing an efficient non-viral gene delivery system for localized therapeutic gene transfer. Methods of using the vectors to overcome biological barriers including mucus gel and extracellular matrix are provided. Methods of formulating the vectors are also provided.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: May 18, 2021
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Justin Hanes, Jung Soo Suk, Panagiotis Mastorakos
  • Patent number: 10993911
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 4, 2021
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10993912
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: May 4, 2021
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10912848
    Abstract: The present invention provides a dual-purpose photoacoustic tomography (PAT)/ultrasound contrast agent comprising: (a) a micro-bubble containing gas and porphyrin therein; and (b) nanoparticles bound on a surface of the micro-bubble and containing a drug. The contrast agent of the present invention can be used in both the ultrasound diagnosis and the photoacoustic image diagnosis, and can significantly increase the accuracy of photoacoustic images.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: February 9, 2021
    Assignee: IMGT CO, LTD.
    Inventors: Hyun Cheol Kim, Hyung Won Moon, Jin Ho Chang
  • Patent number: 10786486
    Abstract: Provided herein are pharmaceutical formulations of dry-powder bendamustine suitable for pharmaceutical use. Also provided are methods of producing dry-powder bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: September 29, 2020
    Inventor: Vasilios Voudouris
  • Patent number: 10773231
    Abstract: This invention relates to a process for colloidosome-type microcapsules elaboration from solid particles microcapsules obtained by ionic gelation. In the process, an (O/W) type emulsion is initially generated stabilized with the solid particles microcapsules, and then the particles are fixed to the interface by adsorption of polyelectrolytes, cross-linking, heat treatment or fatty coating, generating the colloidosome with the water-insoluble phase encapsulated in the core and covered by the shell particles.
    Type: Grant
    Filed: June 18, 2016
    Date of Patent: September 15, 2020
    Assignees: Nexentia S.A.S., Universidad de Antioquia
    Inventors: Herley Casanova, César Augusto Pérez Zapata
  • Patent number: 10772833
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: September 15, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10765741
    Abstract: This document provides methods and materials related to treating cancer (e.g., skin cancer). For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., Abraxane®/anti-VEGF polypeptide antibody complexes) to treat cancer (e.g., skin cancer) are provided.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: September 8, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10751293
    Abstract: A multilayered polymer composite film includes a water-soluble polymer matrix and a plurality of fibers embedded within the water soluble polymer matrix. The fibers include a water insoluble polymer material and at least one of a non-polymeric hydrophobic therapeutic agent or a non-polymeric hydrophobic cosmetic agent incorporated in the water insoluble polymer material. The fibers have a rectangular cross-section, and extend the entire length of the multilayered polymer composite film.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: August 25, 2020
    Assignee: Case Western Reserve University
    Inventors: Eric Baer, Gary E. Wnek, Mohammad Mofidfar, Jia Wang
  • Patent number: 10711040
    Abstract: The present invention relates to novel low substituted polymyxins and compositions thereof.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: July 14, 2020
    Assignee: XELLIA PHARMACEUTICALS APS
    Inventors: Vidar Bjornstad, Solvi Gunnes, Torben Koch, Claes Melander
  • Patent number: 10617648
    Abstract: The present invention provides for method of improving flowability and loose bulk density of functionalized natural- and/or synthetic calcium carbonate comprising material, to the use of such improved material in ready to use granules and thereof produced dispersible dosage forms.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: April 14, 2020
    Assignee: Omya International AG
    Inventors: Leonie Wagner-Hattler, Maxim Puchkov, Jörg Huwyler, Tanja Stirnimann, Carolina Diaz Quijano, Joachim Schoelkopf, Patrick A. C. Gane, Daniel E. Gerard
  • Patent number: 10611908
    Abstract: Biocompatible block copolymer micelles for use in mucoadhesive drug delivery are provided. The micelles comprise a degradable hydrophobic polymer, a degradable synthetic hydrophilic polymer and a mucoadhesive polymer. The micelles are particularly useful for ophthalmic uses.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: April 7, 2020
    Assignee: McMaster University
    Inventors: Heather Sheardown, Graeme Prosperiporta, Stephanie Kedzior, Benjamin Muirhead
  • Patent number: 10568992
    Abstract: The present invention relates to the production of endothelialized matrices and materials from immature endothelial cells using substrates to which particular peptides have been grafted. The resultant substrates can be used to capture and support immature endothelial cells. Further, the methods and compositions of the present invention provide viable cell delivery platforms that allow for production and provision of endothelialized medical devices and implants, including vascular grafts, stents, shunts, and valves, endothelialized surfaces and channels for in vitro testing devices, including microfluidic chips, and materials that support vascularization such as for use in engineered tissues. The present invention includes novel methods required for the successful production of cellularized substrates, systems and components used for the same, and methods of using the resultant cell and tissue compositions.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: February 25, 2020
    Assignee: Auburn University
    Inventors: Elizabeth A. Lipke, Wen Jun Seeto
  • Patent number: 10561161
    Abstract: Comestible products, for example beverage products, are disclosed containing encapsulated probiotic bacteria having resistance to subjection to at least thermal and acidic conditions. Beverage products include at least one aqueous liquid and capsules comprising a gelled mixture of alginate and denatured protein, and probiotic bacteria entrapped within the gelled mixture. The average particle size of the capsules is optionally less than 1000 microns (?m) in diameter, such as less than 500 ?m in diameter. Methods are provided for making such encapsulated probiotics by providing a mixture comprising sodium alginate, denatured protein and active probiotic cells, and combining the mixture with a divalent cation to initiate cold gelation of the sodium alginate and denatured protein to form a second mixture. The second mixture is passed through an opening having a diameter of less than 1000 ?m to form capsules. The weight ratio of protein to alginate is from 1:1 to 9:1.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: February 18, 2020
    Assignees: Pepsico, Inc., Massey University
    Inventors: Yuan Fang, Breda Kennedy, Teodoro Rivera, Kyoung-Sik Han, Anil Kumar Anal, Harjinder Singh
  • Patent number: 10537131
    Abstract: Electrically heated cigarettes used in an electrical smoking system include a flavoring-release additive and sorbent effective to remove one or more gas-phase constituents of mainstream tobacco smoke. The flavoring-release additive includes gamma cyclodextrin and at least one flavoring. Flavoring is released in a cigarette upon the flavoring-release additive reaching at least a minimum temperature during smoking. The flavoring-release additive can have various forms including, for example, powder and films.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: January 21, 2020
    Assignee: Philip Morris USA Inc.
    Inventors: Munmaya K. Mishra, Susan E. Wrenn, Jay A Fournier
  • Patent number: 10370434
    Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: August 6, 2019
    Assignee: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON
    Inventors: Laura Soucek, Marie-Eve Beaulieu
  • Patent number: 10364283
    Abstract: The present invention relates to a collagen hydrolysate which is produced by enzymatic hydrolysis of type-B bone gelatin, wherein the collagen hydrolysate is formed from peptides of which at least 50% by weight, in particular at least 70% by weight have a molecular weight of 1,500 Da to 3,500 Da, and which have a mean molecular weight in the range from 4,000 Da to 8,000 Da, in particular in the range from 4,500 Da to 6,000 Da. The invention also relates to the use of this collagen hydrolysate as an active ingredient to maintain and/or improve the health of the bones, in particular to prevent and/or treat osteoporosis. The invention further relates to a nutritional supplement which comprises the collagen hydrolysate.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: July 30, 2019
    Assignee: GELITA AG
    Inventors: Steffen Oesser, Monika Giesen-Wiese, Hans-Ulrich Frech, Stephan Hausmanns
  • Patent number: 10328155
    Abstract: The disclosure describes nanocarried and/or microcarried jasmonate compounds and their pharmaceutical compositions, as well as use thereof for treating or preventing angiogenesis-related or NF-?B-related disorders. Also disclosed are methods of making the nanocarried and/or microcarried compounds and their compositions.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: June 25, 2019
    Assignee: NANOCARE TECHNOLOGIES, INC.
    Inventor: Jose E. Fehr Pereira Lopes
  • Patent number: 10300016
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 28, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10292909
    Abstract: The disclosure provides biocompatible dental material that is moldable and biodegradable and provides sustained and/or controlled delivery of one or more local anesthetics within a dental cavity or space. Such dental material is customizable for the size and shape needed for a particular patient or particular application. The dental material may also provide customizable sustained and/or controlled delivery of one or more local anesthetics.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: May 21, 2019
    Assignees: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, RESEARCH TRIANGLE INSTITUTE
    Inventors: Leah Marie Johnson, Ginger Denison Rothrock, Sarah Dorothy Shepherd, Sandra Cordel O'Buckley, Andrea Gail Neely
  • Patent number: 10232046
    Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: March 19, 2019
    Assignee: Baxter International Inc.
    Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
  • Patent number: 10207252
    Abstract: The present disclosure relates to the use of pristine and surface functionalized cellulose nanocrystal (CNC) incorporated hydrogel beads as adsorbent materials for water treatment applications. Here the hydrogel beads were prepared by ionic crosslinking of biopolymer sodium alginate using calcium chloride.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: February 19, 2019
    Inventors: Nishil Mohammed, Nathan Grishkewich, Kam Chiu Tam, Richard Berry
  • Patent number: 10208308
    Abstract: The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flue infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and prevention orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: February 19, 2019
    Assignee: Socpra Sciences Sante Et Humaines S.E.C.
    Inventors: Martin Richter, Richard Leduc, Eloic Colombo, Eric Marsault
  • Patent number: 10182996
    Abstract: Described herein are polymeric nanoparticles that include a therapeutic agent, and methods of making and using such therapeutic nanoparticles. In some embodiments, the contemplated nanoparticles may include an excipient.
    Type: Grant
    Filed: July 5, 2015
    Date of Patent: January 22, 2019
    Assignee: Pfizer Inc.
    Inventor: Hong Wang
  • Patent number: 10172947
    Abstract: A composition including hydrophobized chitosan can be used as an antiparasitic and/or antifungal agent or in the treatment of parasitic and/or fungal infections. The composition may include an antifungal agent and hydrophobized chitosan. The antifungal agent can be in association with the hydrophobized chitosan, with the latter being more preferably in the particle form, or the antifungal agent can be encapsulated in particles including the hydrophobized chitosan. The use of the composition as an antifungal agent or in the treatment of fungal infections, and a method for manufacturing the composition are also described.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: January 8, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIFQUE (CNRS), UNIVERSITE PARIS-SUD 11
    Inventors: Kawthar Bouchemal, Christian Bories, Philippe Loiseau, Christine Vauthier-Holtzscherer, Sebastien Pomel, Benedicte Pradines
  • Patent number: 10124068
    Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: November 13, 2018
    Assignee: Baxter International, Inc.
    Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
  • Patent number: 10092660
    Abstract: The invention relates to solid compositions that may be suitable for administering a therapeutic agent to a subject. The invention also relates to methods of making such solid compositions. The invention further relates to methods of treating a disease, condition, or disorder by administering to a subject such solid compositions.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: October 9, 2018
    Assignee: STC.UNM
    Inventors: Hugh Smyth, Ibrahim M. El-Sherbiny
  • Patent number: 10047128
    Abstract: The present invention is a peptide lock that comprises at least one peptide that is genetically encoded into the Adeno-associated virus (AAV) capsid that block biologically active domains on the virus capsid surface. The peptide lock, can be processed by biological enzymes to restore biological behavior of the capsid-displayed domains, thus ‘decoding the lock’ or opening the lock. A method of forming the peptide lock comprises providing at least one peptide, providing an Adeno-associated virus capsid and genetically inserting the at least one peptide into the Adeno-associated virus capsid to block the biologically active domains on the virus capsid surface.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: August 14, 2018
    Assignee: WILLIAM MARSH RICE UNIVERSITY
    Inventors: Justin Judd, Junghae Suh, Jonathan Silberg
  • Patent number: 10022410
    Abstract: The present invention relates generally to agents and devices for promoting hemostasis and, more particularly, to an extract of a plant-based “Traditional Chinese Medicinal” product and devices incorporating such agents for the delivery thereof to bleeding wounds.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: July 17, 2018
    Assignee: Ethicon, Inc.
    Inventors: Yi-Lan Wang, Xintian Ming